BioCentury | Mar 24, 2014
Company News

Qiagen sales and marketing update

...Canada, Japan, Australia, Taiwan and Russia. Qiagen gained the test through its 2011 acquisition of Cellestis Ltd....
BioCentury | Jan 16, 2012
Company News

Qiagen, Max Planck Institute for Infection Biology deal

...modular automation platform and serve as a reflex test following Qiagen's QuantiFERON-TB Gold test. Qiagen's Cellestis Ltd....
...for detecting latent TB by testing blood samples for systemically amplified molecular components. Qiagen acquired Cellestis...
BioCentury | Sep 5, 2011
Company News

Cellestis, Qiagen deal

...share. The price values Cellestis at about A$359 million ($382.3 million) (see BioCentury, July 18). Cellestis Ltd....
BioCentury | Jul 18, 2011
Company News

Cellestis, Qiagen deal

...premium to Cellestis' close of A$3 on April 1, before the original deal was proposed. Cellestis'...
...to complete the deal successfully and "with as much certainty as possible"(see BioCentury, April 11). Cellestis Ltd....
BioCentury | Jul 18, 2011
Finance

Highlights of weekly biotech stock moves

...other tumor types and then will seek a partner for Phase III testing and commercialization. Cellestis Ltd....
...cash. The new price is 7% above Qiagen's original A$3.55 per share offer in April. Cellestis'...
...off €0.63 to €12.82 last week, while the stock lost $0.89 to $18.28 on NASDAQ. Cellestis...
BioCentury | Jul 12, 2011
Company News

Qiagen bumps up Cellestis offer

...Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN) increased its proposal to acquire Australian diagnostics company Cellestis Ltd. (ASX:CST) to A$3.80...
...price is 7% above the original A$3.55 per share offer that Qiagen proposed in April. Cellestis'...
...at a meeting slated for the end of July (see BioCentury Extra, April 4) . Cellestis...
BioCentury | Apr 11, 2011
Company News

Cellestis, Qiagen deal

...Qiagen will acquire Australian diagnostics company Cellestis for A$3.55 per share or A$341 million ($354.4 million...
...share or A$341 million ($354.4 million) in cash. The price is an 18% premium to Cellestis'...
...deal is subject to Cellestis shareholder approval at a meeting slated for June. Qiagen said Cellestis'...
BioCentury | Apr 11, 2011
Finance

Regulatory milestones

...Feb. 21) . Separately, sanofi-aventis Group (Euronext:SAN; NYSE:SNY) last week completed its acquisition of Genzyme. Cellestis Ltd....
...million ($354.4 million) in cash. The deal is subject to Cellestis shareholder approval in June. Cellestis...
BioCentury | Apr 5, 2011
Company News

Qiagen to acquire Cellestis

...Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN) will acquire Australian diagnostics company Cellestis Ltd. (ASX:CST) for A$3.55 per share or...
...share or A$341 million ($354.4 million) in cash. The price is an 18% premium to Cellestis'...
...deal is subject to Cellestis shareholder approval at a meeting slated for June. Qiagen said Cellestis'...
BioCentury | Sep 9, 2010
Tools & Techniques

Identifying TB carriers at risk

...diagnostics on the market that detect both active and latent TB infections: tuberculin skin testing, Cellestis Ltd....
...thus who would benefit from preventative therapy," said Jim Rothel, CSO and executive director of Cellestis...
...online Sept. 9, 2010 Companies and Institutions Mentioned Baylor Health Care System , Dallas, Texas Cellestis Ltd....
Items per page:
1 - 10 of 22
BioCentury | Mar 24, 2014
Company News

Qiagen sales and marketing update

...Canada, Japan, Australia, Taiwan and Russia. Qiagen gained the test through its 2011 acquisition of Cellestis Ltd....
BioCentury | Jan 16, 2012
Company News

Qiagen, Max Planck Institute for Infection Biology deal

...modular automation platform and serve as a reflex test following Qiagen's QuantiFERON-TB Gold test. Qiagen's Cellestis Ltd....
...for detecting latent TB by testing blood samples for systemically amplified molecular components. Qiagen acquired Cellestis...
BioCentury | Sep 5, 2011
Company News

Cellestis, Qiagen deal

...share. The price values Cellestis at about A$359 million ($382.3 million) (see BioCentury, July 18). Cellestis Ltd....
BioCentury | Jul 18, 2011
Company News

Cellestis, Qiagen deal

...premium to Cellestis' close of A$3 on April 1, before the original deal was proposed. Cellestis'...
...to complete the deal successfully and "with as much certainty as possible"(see BioCentury, April 11). Cellestis Ltd....
BioCentury | Jul 18, 2011
Finance

Highlights of weekly biotech stock moves

...other tumor types and then will seek a partner for Phase III testing and commercialization. Cellestis Ltd....
...cash. The new price is 7% above Qiagen's original A$3.55 per share offer in April. Cellestis'...
...off €0.63 to €12.82 last week, while the stock lost $0.89 to $18.28 on NASDAQ. Cellestis...
BioCentury | Jul 12, 2011
Company News

Qiagen bumps up Cellestis offer

...Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN) increased its proposal to acquire Australian diagnostics company Cellestis Ltd. (ASX:CST) to A$3.80...
...price is 7% above the original A$3.55 per share offer that Qiagen proposed in April. Cellestis'...
...at a meeting slated for the end of July (see BioCentury Extra, April 4) . Cellestis...
BioCentury | Apr 11, 2011
Company News

Cellestis, Qiagen deal

...Qiagen will acquire Australian diagnostics company Cellestis for A$3.55 per share or A$341 million ($354.4 million...
...share or A$341 million ($354.4 million) in cash. The price is an 18% premium to Cellestis'...
...deal is subject to Cellestis shareholder approval at a meeting slated for June. Qiagen said Cellestis'...
BioCentury | Apr 11, 2011
Finance

Regulatory milestones

...Feb. 21) . Separately, sanofi-aventis Group (Euronext:SAN; NYSE:SNY) last week completed its acquisition of Genzyme. Cellestis Ltd....
...million ($354.4 million) in cash. The deal is subject to Cellestis shareholder approval in June. Cellestis...
BioCentury | Apr 5, 2011
Company News

Qiagen to acquire Cellestis

...Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN) will acquire Australian diagnostics company Cellestis Ltd. (ASX:CST) for A$3.55 per share or...
...share or A$341 million ($354.4 million) in cash. The price is an 18% premium to Cellestis'...
...deal is subject to Cellestis shareholder approval at a meeting slated for June. Qiagen said Cellestis'...
BioCentury | Sep 9, 2010
Tools & Techniques

Identifying TB carriers at risk

...diagnostics on the market that detect both active and latent TB infections: tuberculin skin testing, Cellestis Ltd....
...thus who would benefit from preventative therapy," said Jim Rothel, CSO and executive director of Cellestis...
...online Sept. 9, 2010 Companies and Institutions Mentioned Baylor Health Care System , Dallas, Texas Cellestis Ltd....
Items per page:
1 - 10 of 22